JAMES DYSON: Open Payments
NPI 1467937854 · WOODBRIDGE, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$806 in 36 payments from 16 companies in 2025. Trend: 2023 $1,194 · 2024 $1,275 · 2025 $806
Food & beverage: $806
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 7 | $145 |
| Lilly USA, LLC | 5 | $104 |
| Novartis Pharmaceuticals Corporation | 4 | $95 |
| ABBVIE INC. | 3 | $72 |
| Amgen Inc. | 2 | $58 |
| GENZYME CORPORATION | 2 | $57 |
| Galderma Laboratories, L.P. | 3 | $47 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | 1 | $34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $29 |
Products named: TREMFYA, DUPIXENT, SKYRIZI, COSENTYX, TALTZ, NEMLUVIO, EBGLYSS, ILUMYA.
Industry payments across VA — which companies pay providers there.
